Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Anglonordic Life Science Conference, London, United Kingdom 18 April 2024 Attending: Simon Kerry, Chief […]
Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.
Dr Price brings over 20 years of experience in drug discovery and development, across pharma and biotech Southampton, UK, 18 September 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a game-changing, functional drug discovery platform, today announces the appointment of Dr Sally Price as its Vice President of Biology. Dr […]
Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Southampton, UK, 2 May 2023 – Curve Therapeutics (Curve), a […]
Our CSO, Prof Ali Tavassoli, discusses his career, academic research and experience with building a Biotech company with Tom Froggatt in the “Careers in Drug Discovery” podcast. Listen to Ali and Tom’s conversation on iTunes or Spotify.
Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables direct discovery of functionally active molecules against difficult to drug targets expressed in their native intracellular environment Southampton, UK, 16th February 2022: Curve Therapeutics (Curve), a private biotechnology company pioneering […]
Southampton, UK, 31st July 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces its participation in the UK BioIndustry Association’s 2021 Parliament Day. This annual event gives senior representatives from the UK biotech sector the opportunity to meet with MPs, Ministers and Peers to discuss key […]
Southampton, UK, 31st March 2021. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces the grant of US Patent 10,962,549 describing novel Microcycles that inhibit both HIF-1 and HIF-2. Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the […]
Southampton, UK, 31st July 2020. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces an investment of £2.25 Mn from Epidarex Capital, a trans-Atlantic venture capital firm that invests in early-stage, high growth life science and health technology companies in emerging and under-ventured research hubs within the […]
Southampton, UK, 27th June 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces a seed investment of £2.25 Mn from Advent Life Sciences, a leading trans-Atlantic venture investor focused on building innovative Life Sciences businesses in the UK, Europe and the USA. Curve originated from world-leading […]
